BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)

Phase 3

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Placebo
Drug: Irbesartan

First Posted Date: 2006-07-14

Last Posted Date: 2010-02-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 44

Registration Number: NCT00352560

Locations: 🇪🇸
Local Institution, Madrid, Spain

A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies

Phase 1

Terminated

Conditions: Advanced Solid Malignancies

Interventions: Drug: BMS-663513

First Posted Date: 2006-07-12

Last Posted Date: 2009-09-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 45

Registration Number: NCT00351325

Locations: 🇺🇸
University Of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸
Magee-Womens Hospital Of Upmc, Pittsburgh, Pennsylvania, United States
🇺🇸
University Of Virginia, Charlottesville, Virginia, United States

and more 2 locations

Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

Phase 2

Withdrawn

Conditions: Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia

First Posted Date: 2006-07-07

Last Posted Date: 2016-02-17

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00349518

Locations: 🇬🇧
Local Institution, Birmingham, West Midlands, United Kingdom
🇵🇱
Local Instiution, Lodz, Poland

A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept
Drug: Placebo

First Posted Date: 2006-06-28

Last Posted Date: 2011-04-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 194

Registration Number: NCT00345748

Locations: 🇯🇵
Local Institution, Tochigi, Japan

Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: Paclitaxel

First Posted Date: 2006-06-27

Last Posted Date: 2009-11-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 53

Registration Number: NCT00344552

Locations: 🇯🇵
Local Institution, Saitama, Japan

Study to Evaluate The Analgesic Efficacy and Safety of Intravenous Paracetamol in Subjects With Postoperative Pain After Total Hip Arthroplasty

Phase 4

Completed

Conditions: Pain

Interventions: Drug: Placebo
Drug: Paracetamol

First Posted Date: 2006-06-26

Last Posted Date: 2015-11-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 86

Registration Number: NCT00344045

Locations: 🇪🇸
Local Institution, Vizcaya, Spain

Study of Dasatinib (BMS-354825) in Patients With Solid Tumors

Phase 1

Completed

Conditions: Tumors

Interventions: Drug: Dasatinib

First Posted Date: 2006-06-20

Last Posted Date: 2010-12-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT00339144

Locations: 🇯🇵
Local Institution, Koto-Ku, Tokyo, Japan

Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan

Phase 1

Completed

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: Dasatinib

First Posted Date: 2006-06-16

Last Posted Date: 2011-04-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 48

Registration Number: NCT00337454

Locations: 🇯🇵
Local Institution, Tokyo, Japan

Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression

Phase 3

Completed

Conditions: Human Immunodeficiency Virus (HIV) Infections

Interventions: Drug: Atazanavir + Ritonavir

First Posted Date: 2006-06-16

Last Posted Date: 2010-07-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 61

Registration Number: NCT00337467

Locations: 🇪🇸
Local Institution, Malaga, Spain

A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Paclitaxel
Drug: cisplatin

First Posted Date: 2006-06-16

Last Posted Date: 2010-02-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 50

Registration Number: NCT00337532

Locations: 🇰🇷
Local Institution, Seoul, Korea, Republic of
🇰🇷
Local Insitution, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy